Alecnib(150mg)'s effectiveness depends on the cancer stage, patient's health, and treatment response. Clinical trials show it shrinks tumors and improves survival rates in ALK-positive NSCLC patients. However, not everyone responds, and it's crucial to be patient. Regular imaging tests help monitor response and adjust dosage as prescribed by a doctor.